

Hemogenyx Pharmaceuticals plc 04 May 2020

## **Hemogenyx Pharmaceuticals plc**

("Hemogenyx" or the "Company")

## TR-1: Standard form for notification of major holdings

**NOTIFICATION OF MAJOR HOLDINGS** (to be sent to the relevant issuer <u>and</u> to the FCA in Microsoft Word format if possible)<sup>i</sup>

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:	HEMOGENYX PHARMACEUTICALS PLC					
1b. Please indicate if the issuer is a non-UK issuer (please	<b>1b. Please indicate if the issuer is a non-UK issuer</b> (please mark with an "X" if appropriate)					
Non-UK issuer						
2. Reason for the notification (please mark the appropriate box or boxes with an "X")						
An acquisition or disposal of voting rights						
An acquisition or disposal of financial instruments						
An event changing the breakdown of voting rights						
Other (please specify) <sup>iii</sup> :						
3. Details of person subject to the notification obligation	<b>j</b> îv					
Name	Craig Auringer					
City and country of registered office (if applicable)  London UK						
<b>4. Full name of shareholder(s)</b> (if different from 3.) <sup>v</sup>						
Name						



applicable)

City and country of re	egistered office (if appli	cable)			
5. Date on which the threshold was crossed or reached <sup>vi</sup> :			April 28,2020		
6. Date on which issuer notified (DD/MM/YYYY):			May 2, 2020	)	
7. Total positions of p	person(s) subject to the	notification	obligation 2	27	
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer <sup>vii</sup>
Resulting situation on the date on which threshold was crossed or reached	6.9			6.9	397253969
Position of previous notification (if	7.9			7.9	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached						
A: Voting rights attached to shares						
Class/type of	Number of voting ri	ghts <sup>ix</sup>	% of voting rights			
shares	Direct	Indirect	Direct	Indirect		
ISIN code (if possible)	(Art 9 of Directive 2004/109/EC) (DTR5.1)	(Art 10 of Directive 2004/109/EC) (DTR5.2.1)	(Art 9 of Directive 2004/109/EC) (DTR5.1)	(Art 10 of Directive 2004/109/EC) (DTR5.2.1)		
GB00BYX3WZ24	27,072,000		6.9			
SUBTOTAL 8. A	27,07	27,072,000				

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))					
Type of financial instrument	Expiration date <sup>x</sup>	Exercise/ Conversion Period <sup>™</sup>	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights	



	SUBTOTAL 8. B 1	

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))							
Type of financial instrument	Expiration date <sup>x</sup>	Exercise/ Conversion Period *i	Physical or cash settlement*i	Number of voting rights	% of voting rights		
	1		SUBTOTAL 8.B.2				

9. Information in relation to the person subject to the notification obligation (please mark the							
applicable box with an "X")							
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer <sup>xiii</sup>							
<u>Full</u> chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity <sup>xiv</sup> (please add additional rows as necessary)							
Name™	% of voting rights % of voting rights through financial equals or is higher than the notifiable threshold  % of voting rights Total of both if it equals or is higher than the notifiable threshold						



10. In case of proxy votin	10. In case of proxy voting, please identify:				
Name of the proxy holder					
The number and % of voti	ng rights held				
The date until which the vo	oting rights will be held				
11. Additional information	on <sup>xi</sup>				
Place of completion	London				
Date of completion	May 2 2020				



## TR-1: Standard form for notification of major holdings

**NOTIFICATION OF MAJOR HOLDINGS** (to be sent to the relevant issuer <u>and</u> to the FCA in Microsoft Word format if possible)<sup>i</sup>

	uer or the underlying is ich voting rights are at	HEMOGENYX PHARMACEUTICALS PLC				
1b. Please indicate if	the issuer is a non-UK i	ssuer (pleas	e mark with a	ın "X" if appropriate)		
Non-UK issuer						
2. Reason for the not	<b>ification</b> (please mark th	e appropriat	e box or boxe	es with an "X")		
An acquisition or disp	oosal of voting rights					х
An acquisition or disp	oosal of financial instrun	nents				
An event changing th	An event changing the breakdown of voting rights					
Other (please specify) <sup>iii</sup> :						
3. Details of person subject to the notification obligation <sup>™</sup>					<u> </u>	
Name			Craig Auringer			
City and country of re	egistered office (if applic	cable)	London UK			
4. Full name of share	holder(s) (if different fro	m 3.) <sup>v</sup>				
Name						
City and country of re	egistered office (if applic	cable)				
5. Date on which the reached <sup>vi</sup> :	threshold was crossed	or	May 1,2020			
6. Date on which issu	er notified (DD/MM/Y)	YYY):	May 2, 2020			
7. Total positions of p	person(s) subject to the	notification	obligation 2	27		
attached to shares  (total of 8, A)  through			ing rights financial ments B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total numbe voting rights issuer <sup>vii</sup>	
Resulting situation on the date on which threshold was crossed or reached	5.9			5.9	397253969	



Position of previous			
notification (if	6.9	6.9	
applicable)			

A: Voting rights attached to shares						
Class/type of	Number of voting ri	ghts <sup>ix</sup>	% of voting rights			
shares	Direct	Indirect	Direct	Indirect		
ISIN code (if possible)	(Art 9 of Directive 2004/109/EC) (DTR5.1)	(Art 10 of Directive 2004/109/EC) (DTR5.2.1)	(Art 9 of Directive 2004/109/EC) (DTR5.1)	(Art 10 of Directive 2004/109/EC) (DTR5.2.1)		
GB00BYX3WZ24	23,354,250		5.9			
SUBTOTAL 8. A	23,354,250		5.9			

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))						
Type of financial instrument	Expiration date <sup>x</sup>	Exercise/ Conversion Period <sup>xi</sup>	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights		
	- 1	SUBTOTAL 8. B 1				

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))								
Type of financial instrument	Expiration date <sup>x</sup>	Exercise/ Conversion Period *i	Physical or cash settlement*i	Number of voting rights	% of voting rights			
	ı		SUBTOTAL 8.B.2					



9. Information in relation to the person subject to the notification obligation (please mark the									
applicable box with an "X"	)								
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer <sup>xiii</sup>									
<u>Full</u> chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity <sup>xiv</sup> (please add additional rows as necessary)									
Name	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold						
10. In case of proxy voti		1							
Name of the proxy holder									
The number and % of voti	ng rights held								
The date until which the v	oting rights will be held								
11. Additional information	<b>on</b> <sup>xvi</sup>								
Place of completion	London								
Date of completion									
Date of completion	May 2 2020								